Board of Trustees of The Leland Stanford Junior University’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Board of Trustees of The Leland Stanford Junior University’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-736,827	Closed	-$5.3M	–	29
2019 Q4	$5.3M	Sell	736,827 -212,616	-22%	-$1.92M	0.64%	11
2019 Q3	$10.3M	Hold	949,443	–	–	1.11%	5
2019 Q2	$12.3M	Buy	949,443 +40,199	+4%	+$534K	1.73%	4
2019 Q1	$8.98M	Hold	909,244	–	–	1.25%	5
2018 Q4	$9.46M	Buy	+909,244	New	+$11M	1.15%	6

Other funds holding LOGC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Board of Trustees of The Leland Stanford Junior University's LOGC Position: Q1 2020 in Review

Board of Trustees of The Leland Stanford Junior University sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2020, closing a stake of 736,827 shares — an estimated $5.3M sold.

Board of Trustees of The Leland Stanford Junior University first reported a position in LOGC in Q4 2018 and held it in 5 quarters. The position peaked at $12.3M in Q2 2019. 43 funds tracked by Wall St. Rank hold LOGC as of Q1 2020.

Board of Trustees of The Leland Stanford Junior University reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Board of Trustees of The Leland Stanford Junior University sold 736,827 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $5.3M.
Board of Trustees of The Leland Stanford Junior University first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 5 quarters.
Board of Trustees of The Leland Stanford Junior University's LogicBio Therapeutics, Inc. Common Stock position peaked at $12.3M in Q2 2019.
43 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Board of Trustees of The Leland Stanford Junior University's 13F filing for Q1 2020, filed 13 May 2020.